Despite being used to dealing with drugs that are incredibly expensive, the high cost of Sovaldi presents a new problem for state Medicaid programs, according to Matt Salo, the executive director of the National Association of Medicaid Directors.
Despite being used to dealing with drugs that are incredibly expensive, the high cost of Sovaldi presents a new problem for state Medicaid programs, according to Matt Salo, the executive director of the National Association of Medicaid Directors.
The problem, he explained, isn’t that the drug costs so much, because treatments for kids with cystic fibrosis are much more; the problem is that it costs so much and is needed for so many people.
“It’s not going to work within the limited finite budget that is Medicaid, because that means something else is going to have to give,” Mr Salo said. “If you double the pharmacy spend, what’s going to give? Long-term care? Nursing homes for seniors? Vaccinations for kids?”
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More